Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Written by Customer Service on March 5, 2024. Posted in Earnings Releases And Operating Results.

Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 million Reaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual Film in March 2024 Reaffirms anticipated FDA decision on Libervant™ (diazepam) Buccal Film application in April 2024 Provides full year 2024 financial guidance Hosts investment community conference call on March 6, 2024 WARREN, N.J., March 05, 2024 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a progress update on the key 2024 objectives previously...

Inspirato Announces 2023 Revenue and Adjusted EBITDA within Previously Guided Ranges, Provides 2024 Guidance

Written by Customer Service on March 5, 2024. Posted in Earnings Releases And Operating Results.

DENVER, March 05, 2024 (GLOBE NEWSWIRE) — Inspirato Incorporated (“Inspirato” or the “Company”) (NASDAQ: ISPO), the innovative luxury travel club, today announced its 2023 fourth quarter and full-year results and provided 2024 guidance aimed at improving its path to profitability. Except as otherwise stated, all financial results discussed below are presented in accordance with generally accepted accounting principles in the United States of America, or GAAP. As supplemental information, we have provided certain additional non-GAAP financial measures in this press release’s supplemental tables, and such supplemental tables include a reconciliation of these non-GAAP measures to our GAAP results. The sum of individual metrics may not always equal total amounts indicated due to rounding. 2023 Fourth Quarter and Full-Year Highlights: Full-year...

Fitell Corporation Announces First Half-Year Financial Results

Written by Customer Service on March 5, 2024. Posted in Earnings Releases And Operating Results.

TAREN POINT, Australia, March 05, 2024 (GLOBE NEWSWIRE) — Fitell Corporation (Nasdaq: FTEL) (“Fitell” or the “Company”), an online retailer of gym and fitness equipment in Australia, today announced its half-year financial results for the six months ended December 31, 2023. Six-month Period ended December 31, 2023 Financial Highlights Revenue was $2.1 million, a decrease of $0.9 million or 30.5% compared to the same period in 2022. Gross profit was $0.85 million, a decrease of $745,555 or 46.8% from the same period in 2022. Revenue by Categories vs. Same Period of Prior Year Revenue Change from Six-month Period ended December 31, 2022 US$ % US$ % Merchandise revenue 2,007,562 94.6% (144,310 ) -6.7% Sales of consumable products 0 0 (605,415 ) -100.0% Revenue from licensing customers 115,557 5.4% (181,308 ) -61.1% Merchandise...

Canoe EIT Income Fund Announces March 2024 Monthly Distribution

Written by Customer Service on March 5, 2024. Posted in Dividend Reports And Estimates.

CALGARY, Alberta, March 05, 2024 (GLOBE NEWSWIRE) — Canoe EIT Income Fund (the “Fund”) (TSX – EIT.UN) announces the March 2024 monthly distribution of $0.10 per unit. The distribution will be paid on April 15, 2024 to unitholders of record on March 22, 2024. The ex-distribution date for this distribution is March 21, 2024. About Canoe EIT Income FundCanoe EIT Income Fund is one of Canada’s largest closed-end investment funds, designed to maximize monthly distributions and capital appreciation by investing in a broadly diversified portfolio of high quality securities. The Fund is listed on the TSX under the symbol EIT.UN, and is actively managed by Robert Taylor, Senior Vice President and Chief Investment Officer, Canoe Financial. About Canoe Financial Canoe Financial is one of Canada’s fastest growing independent mutual fund...

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Written by Customer Service on March 5, 2024. Posted in Public Companies.

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California. Details for the poster presentation are as follows: Title: Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer modelsDate and Time: Tuesday Apr 9, 2024, 9:00 AM – 12:30 PM PTPoster Session: In Vivo Imaging and Humanized ModelsLocation: Poster Section 9, Poster Board #19Abstract Number: 4195 The abstract is available on the AACR Online Program and will...

<div>W&T Offshore Announces Fourth Quarter and Full Year 2023 Results Including Year-End 2023 Proved Reserves, Provides Guidance for 2024, and Declares Dividend for First Quarter of 2024</div>

W&T Offshore Announces Fourth Quarter and Full Year 2023 Results Including Year-End 2023 Proved Reserves, Provides Guidance for 2024, and Declares Dividend for First Quarter of 2024

Written by Customer Service on March 5, 2024. Posted in Earnings Releases And Operating Results.

HOUSTON, March 05, 2024 (GLOBE NEWSWIRE) — W&T Offshore, Inc. (NYSE: WTI) (“W&T” or the “Company”) today reported operational and financial results for the fourth quarter and full year 2023, including the Company’s year-end 2023 reserve report. Detailed guidance for the first quarter of 2024 and full year 2024 was also provided, and W&T announced its dividend for the first quarter of 2024. This press release includes non-GAAP financial measures, including Adjusted Net (Loss) Income, Adjusted EBITDA, Free Cash Flow, Net Debt and PV-10 which are described and reconciled to the most comparable GAAP measures below in the accompanying tables under “Non-GAAP Information.” Key highlights for the fourth quarter and full year 2023 and since year-end 2023 included: Completed two accretive acquisitions of producing properties...

Bird Construction Inc. Announces 2023 Fourth Quarter and Annual Financial Results

Written by Customer Service on March 5, 2024. Posted in Earnings Releases And Operating Results.

MISSISSAUGA, Ontario, March 05, 2024 (GLOBE NEWSWIRE) — “The robust growth and profitability of Bird’s fourth quarter and full year reflect the power of executing our strategy, the trust and level of collaboration we have achieved with our clients, and the quality of delivery from our dedicated ‘One Bird’ team. Our capabilities to deliver sophisticated work and our position as a leading collaborative construction and maintenance company remain competitive advantages, which we intend to leverage in 2024 and beyond as we continue to focus on growth and margin expansion,” stated Teri McKibbon, President and CEO of Bird Construction. “Supported by a strong balance sheet and ability to generate positive cash flow that allows the Company to invest in profitable organic growth and pursue accretive acquisitions, the Company...

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Written by Customer Service on March 5, 2024. Posted in Earnings Releases And Operating Results.

Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025 NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic...

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Written by Customer Service on March 5, 2024. Posted in Public Companies.

ACR-2316, a novel, selective dual WEE1 and PKMYT1 inhibitor development candidate, designed using AP3 to achieve superior single agent activity, demonstrates potent preclinical activity across studies AP3 identified mechanism of resistance to ACR-368, a clinical-stage CHK1/2 inhibitor, as well as a rational combination treatment to overcome resistance through sensitization to ACR-368 via ultra-low dose gemcitabine WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive...

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

Written by Customer Service on March 5, 2024. Posted in Public Companies.

WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical data on EOS-984, a first-in-class small molecule antagonist targeting equilibrative nucleoside transporter 1 (ENT1), at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, California. Poster Presentation Details Abstract 734, “Inhibition of equilibrative nucleoside transporter 1 relieves intracellular adenosine-mediated immune suppression” Session: Experimental and Molecular Therapeutics: Tumor Microenvironment Date and Time: Sunday, April 7, 2024, 1:30 PM...

Day: March 5, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice